

GLAXOSMITHKLINE PLC
Form 6-K
July 17, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 17 July 2017

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
 - b) Position/status Chief Executive Officer
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
 - c) Price(s) and volume(s)

| Price(s) | Volume(s) |
|--------------------------|-----------|
| £16.2250 | 487.325 |
| n/a (single transaction) | |
 - d) Aggregated information
Aggregated volume Price
 - e) Date of the transaction 2017-07-13
 - f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Manufacturing & Supply
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence
 each ('Ordinary Shares')
 ISIN: GB0009252882
 Increase in notional interest
 in Ordinary Shares following
 the re-investment of
 dividends paid to
 b) Nature of the transaction shareholders on 13 July 2017,
 on Ordinary Shares held in
 the Company's Deferred
 Investment Award
 Programme.

- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.2250 194,930
 n/a (single transaction)

- Aggregated information
 d) A
 aggregated volume Price

- e) Date of the transaction 2017-07-13
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S A Hussain
 b) Position/status President, Global
 Pharmaceuticals
 c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
 platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
 Details of the transaction(s): section to be repeated for (i) each type of
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each
 place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence
 each ('Ordinary Shares')
 ISIN: GB0009252882
 b) Nature of the transaction Increase in notional interest
 in Ordinary Shares following

the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.

| | | |
|---------------------------|--------------------------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | £16.2250 | 243.662 |
| | n/a (single transaction) | |

Aggregated information
d) Aggregated volume Price

| | |
|-----------------------------|------------|
| e) Date of the transaction | 2017-07-13 |
| f) Place of the transaction | n/a |

1. Details of PDMR/person closely associated with them ('PCA')

| | |
|---------------------------------------|------------------------------|
| a) Name | Mr B McNamara |
| b) Position/status | CEO, GSK Consumer Healthcare |
| c) Initial notification/ amendment | Initial notification |

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

| | |
|---------|----------------------|
| a) Name | GlaxoSmithKline plc |
| b) LEI | 5493000HZTVUYLO1D793 |

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

| | |
|--|--|
| a) Description of the financial instrument | GlaxoSmithKline plc American Depositary Shares ('ADSs') |
|--|--|

| | |
|------------------------------|--|
| b) Nature of the transaction | ISIN: US37733W1053 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 July 2017 on ADSs held in the Company's Deferred Investment Award Programme. |
|------------------------------|--|

| | | |
|---------------------------|--------------------------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
| | \$42.4750 | 308.094 |
| d) Aggregated information | n/a (single transaction) | |

Aggregated volume Price

- e) Date of the transaction 2017-07-13
 f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
 a) Name Mr D S Redfern
 b) Position/status Chief Strategy Officer
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
 Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.2250 194.930
 n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2017-07-13
 f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
 a) Name Ms C Thomas

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- b) Position/status Senior Vice President, HR
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £16.2250 | 194,930 |
| n/a (single transaction) | |
- d) Aggregated information
- Aggregated volume Price
- e) Date of the transaction 2017-07-13
- f) Place of the transaction n/a
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr P J T Vallance
- b) Position/status President, R&D
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

| | |
|--|--|
| | ISIN: GB0009252882 |
| b) Nature of the transaction | Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 July 2017 on Ordinary Shares held in the Company's Deferred Investment Award Programme. |
| c) Price(s) and volume(s) | Price(s) Volume(s) £16.2250 243.662 n/a (single transaction) |
| d) Aggregated information Aggregated volume Price | |
| e) Date of the transaction | 2017-07-13 |
| f) Place of the transaction | n/a |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 17, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc